IRESSA(ZD1839)治疗晚期复发性非小细胞肺癌75例  

IRESSA(ZD1839) in treatment for 75 cases with advanced non-small cell lung cancer

作　　者：王志伟[1] 

机构地区：[1]河南省南阳市第二人民医院肿瘤科

出　　处：《中国临床新医学》2009年第1期64-65,共2页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：目的观察Gefitinib（Iressa，ZD1839）作为挽救治疗晚期复发性非小细胞肺癌的疗效及其毒副反应。方法给75例进展期NSCLC病人口服Gefitinib（Iressa，阿斯利康公司提供），每日250mg，于早餐后服用。病人入选标准为复发或者转移的非小细胞肺癌病人，功能状态评分0—2。结果毒副反应：痤疮样皮疹为46．7％，腹泻为28．0％，转氨酶升高为12．0％，恶心、呕吐为13．3％，未观察到间质性肺炎病例。结论ZD1839单药治疗晚期非小细胞肺癌有效，毒副反应小，展示了治疗晚期非小细胞肺癌的广阔的前景。Objective To describe the toxicity and efficacy of Gefitinib （Iressa, ZD1839） used as an ＂ultimum refugium＂ for patients with recurrent NSCLC. Methods Seventy-five patients presenting with advanced NSCLC were treated with 250mg oral gefitinib daily afer the breakfast, the agent were sponsored by the drug company astrazeniea. Eligibility criteria for this study included recurrent or metastatic NSCLC. Results The response rate （CR＋ PR＋ SD）was 37.5% with CR 2.7%, PR 29.3%and SD 24%. Adverse events： rash, diarrhea, step-up of aminotransferase, nausea and vomiting were reported by 46.7%, 28%, 12% and 13.3% respectively. No interstitial lung disease was found. Conclusion ZD1839 has single-agent activity in advanced NSCLC with a satisfactory toxicity profile. It shows good prospect to patients which suffer from advanced and metastatic NSCLC.

关 键 词：ZD1839 非小细胞肺癌 有效率 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]